Sign in
Taking peoplePhase 3

Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, double-blind, placebo-controlled, phase 3 trial PEACH 2

Key facts

Who runs it
Hospices Civils De Lyon
Where
France15 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
580 people, planned
Started
10 Nov 2026
Expected to end
1 Mar 2030
Type of study
Interventional
Record updated
6 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥ 18 years; Spontaneous (non-traumatic) supratentorial intracerebral haemorrhage diagnosed by brain CT or MRI; Onset of neurologic symptoms within 24 hours; NIHSS score on admission ≤ 25; Informed consent given by the patient or his/her impartial witness; Patients benefiting from a social insurance system or a similar system

Who cannot take part

  • Patients who have been part of a clinical study involving another investigational product in the previous 30 days or within 5 half-lives of the other investigational product prior to Screening, whichever is longer, or participant is currently receiving an investigational product
  • Previous history of severe depression, or psychotic disorder or suicidal attempt
  • Intracerebral haemorrhage known or suspected by study investigator to be secondary to trauma, vascular malformation, haemorrhagic transformation of ischaemic stroke, or cerebral tumour
  • Patients with inaugural seizures at the onset of symptoms associated with intracerebral hemorrhage
  • Current use of antiseizure drugs or history of epilepsy
  • Known terminal illness; Known allergy or hypersensitivity to Levetiracetam or other pyrrolidone derivatives, or any of the excipients; Known allergy or hypersensitivity to microcrystalline cellulose or lactose; Being under legal protection
  • Patients with QTc prolongation
  • Severe renal insufficiency (creatinine clearance < 30 ml/min)
  • Patients taking probenecid, methotrexate or macrogol
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

to establish if primary prophylactic antiseizure drug improves functional outcome at 6 months in patients with ICH.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
6 November 2026